Get the Stockscreener App
45.32
0.59%
-0.27
Pre-market:
44.99
-0.33
-0.73%
Enliven Therapeutics Inc stock is traded at $45.32, with a volume of 1.12M.
It is down -0.59% in the last 24 hours and up +49.87% over the past month.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
See More
Previous Close:
$45.59
Open:
$45.97
24h Volume:
1.12M
Relative Volume:
0.84
Market Cap:
$2.71B
Revenue:
-
Net Income/Loss:
$-103.69M
P/E Ratio:
-24.39
EPS:
-1.8579
Net Cash Flow:
$-70.46M
1W Performance:
+16.71%
1M Performance:
+49.87%
6M Performance:
+117.68%
1Y Performance:
+203.96%
1-Day Range:
$44.65
$46.31
1-Week Range:
$38.74
$46.31
52-Week Range:
$14.45
$46.31
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Name
Enliven Therapeutics Inc
Sector
Industry
Phone
720-647-8519
Address
6200 LOOKOUT ROAD, BOULDER
Compare ELVN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
45.32 | 2.71B | 0 | -103.69M | -70.46M | -1.8579 |
VRTX
Vertex Pharmaceuticals Inc
|
436.27 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.87 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
799.65 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
322.11 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
309.66 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Goldman | Buy |
| Dec-13-24 | Initiated | BTIG Research | Buy |
| Sep-09-24 | Initiated | H.C. Wainwright | Buy |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-09-24 | Initiated | Mizuho | Buy |
| Mar-29-23 | Initiated | Jefferies | Buy |
View All
Enliven Therapeutics Inc Stock (ELVN) Latest News
Enliven Therapeutics (ELVN) soars to 5-year high as analysts 'upbeat' - MSN
(ELVN) Volatility Zones as Tactical Triggers - Stock Traders Daily
ELVN Surges Amid Strategic Acquisition Talks and Analyst Upgrades - StocksToTrade
H.C. Wainwright reiterates Enliven Therapeutics stock rating on Terns deal details - Investing.com Canada
Merck’s Acquisition Ups Competition in Pharmaceuticals, Enliven Shines - timothysykes.com
Merck’s Acquisition Sparks Surge in Enliven Therapeutics - StocksToTrade
Enliven Therapeutics Regains Attention as Stock Prices Soar - timothysykes.com
Enliven Therapeutics stock hits 52-week high at $40.66 - Investing.com
Enliven Therapeutics stock hits 52-week high at $40.66 By Investing.com - Investing.com South Africa
Enliven (ELVN) gets higher price targets from HC Wainwright and Mizuho - MSN
Enliven (ELVN) Gets Higher Price Targets From H.C. Wainwright and Mizuho - Insider Monkey
Terns Buyout Deal Ignites Optimism For Enliven Therapeutics’s Blood Cancer Portfolio - MSN
5 Best Performing Stocks of Q1 2026 to Watch for Q2 - Insider Monkey
Enliven Therapeutics stock hits 52-week high at 30.29 USD - Investing.com
25,000-share resale via Jefferies — Enliven Therapeutics (NASDAQ: ELVN) - Stock Titan
[144] Enliven Therapeutics, Inc. SEC Filing - Stock Titan
Q1 EPS Estimate for Enliven Therapeutics Reduced by Analyst - MarketBeat
Assessing Enliven Therapeutics (ELVN) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
Price-Driven Insight from (ELVN) for Rule-Based Strategy - Stock Traders Daily
Enliven Therapeutics CMO Executes $1.2M Stock Sale | Company Update 2026News and Statistics - IndexBox
Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million - AOL.com
Volume Report: Should I trade or invest in Enliven Therapeutics Inc2026 Market WrapUp & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Enliven Therapeutics Insider Sold Shares Worth $1,404,024, According to a Recent SEC Filing - MarketScreener
Enliven (NASDAQ: ELVN) CMO exercises options and sells 40K shares - Stock Titan
Aug PreEarnings: Can Enliven Therapeutics Inc disrupt its industryDip Buying & Low Volatility Stock Recommendations - baoquankhu1.vn
Enliven Therapeutics (NASDAQ:ELVN) Price Target Raised to $56.00 at HC Wainwright - Defense World
ELVN Stock Soars as Merck’s Billion-Dollar Acquisition Validates Strategy - timothysykes.com
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Terns Pharmaceuticals (TERN) - The Globe and Mail
Enliven Therapeutics (NASDAQ:ELVN) Given New $56.00 Price Target at HC Wainwright - MarketBeat
Enliven Therapeutics stock price target raised to $56 by H.C. Wainwright - Investing.com Canada
Enliven Therapeutics (NASDAQ:ELVN) Hits New 12-Month High on Analyst Upgrade - MarketBeat
Enliven Therapeutics (ELVN) Soars to 5-Year High as Analysts ‘Upbeat’ - Insider Monkey
Enliven Reports Q4 Loss; Clinical Milestones Ahead - timothysykes.com
Enliven Therapeutics (ELVN) affiliate files to sell 45,000 shares via Jefferies - Stock Titan
Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up After Analyst Upgrade - marketbeat.com
Enliven Therapeutics (NASDAQ:ELVN) Gains Attention After Price Target Adjustment - kalkinemedia.com
Enliven Therapeutics (NASDAQ:ELVN) Price Target Raised to $45.00 - MarketBeat
Clear Street reiterates Enliven Therapeutics stock Buy on CML opportunity By Investing.com - ca.investing.com
Enliven Therapeutics stock surges 28% on Merck-Terns deal By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Wednesday's Pre-Market SessionAkari Therapeutics (NASDAQ:AKTX), Artelo - Benzinga
ELVN Surges 12%: Clinical Milestone Breaks Barriers and Sparks Biotech Momentum - Bitget
Mizuho raises Enliven Therapeutics price target to $45 on CML data - Investing.com Canada
Enliven Therapeutics (Nasdaq: ELVN) founder files Form 144 to sell 100,000 - Stock Titan
Enliven Therapeutics (NASDAQ:ELVN) Hits New 12-Month HighShould You Buy? - MarketBeat
Enliven Therapeutics stock hits 52-week high at $30.98 By Investing.com - Investing.com Canada
Enliven Therapeutics CMO Collins sells $138,800 in stock By Investing.com - Investing.com Australia
Enliven Therapeutics CMO Collins sells $138,800 in stock - Investing.com
Enliven Therapeutics Inc Stock (ELVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.95%
3.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):